STOCK TITAN

Lower quorum rule adopted by HCW Biologics (NASDAQ: HCWB)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

HCW Biologics Inc. is changing its corporate rules to make it easier to conduct shareholder meetings. On April 15, 2026, the board approved a Bylaw amendment that, effective April 28, 2026, lowers the quorum needed to do business at stockholder meetings.

Going forward, holders of 33 1/3% of the voting power, present in person or by proxy, will be enough to constitute a quorum. Previously, the Bylaws required a majority of the voting power of outstanding shares entitled to vote to be present for business to proceed.

Positive

  • None.

Negative

  • None.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
New quorum threshold 33 1/3% of voting power Quorum for stockholder meetings after April 28, 2026
Prior quorum threshold Majority of voting power Previously required for stockholder meeting quorum
Board approval date April 15, 2026 Date board approved Bylaw amendment
Effective date April 28, 2026 Date amended quorum requirement becomes effective
Exhibit number 3.2a Amendment to the Bylaws of HCW Biologics Inc.
quorum regulatory
"lowers the quorum requirement contained in Section 1.5 of the Bylaws"
A quorum is the minimum number of members needed to officially hold a meeting or make decisions. It ensures that decisions are made with enough participation to represent the group’s interests, much like a majority must be present for a vote to be valid. For investors, understanding quorum is important because it affects when and how important company or organization decisions can be legally made.
Bylaws regulatory
"approved and adopted an amendment to the Company’s Bylaws"
Corporate bylaws are a company's internal rulebook that explains how the business is run day to day — who makes decisions, how directors and officers are chosen, how shareholder meetings are conducted, and procedures for changes or conflicts. For investors, bylaws matter because they shape governance and control, influence how quickly and easily leadership or strategy can change, and can protect or limit shareholder rights much like house rules affect how a household operates.
voting power financial
"holders of thirty-three and one-third percent (33 1/3%) of the voting power"
Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.
emerging growth company regulatory
"Emerging growth company Item 5.03 Amendments to Articles of Incorporation"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Section 1.5 regulatory
"lowers the quorum requirement contained in Section 1.5 of the Bylaws"
false --12-31 0001828673 0001828673 2026-04-15 2026-04-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 15, 2026

 

 

 

HCW Biologics Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-40591   82-5024477
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

2929 N. Commerce Parkway    
Miramar, Florida   33025
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 954 842-2024

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 


Title of each class
  Trading Symbol(s)  
Name of each exchange on which registered
Common Stock, par value $0.0001 per share   HCWB   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On April 15, 2026, the Board of Directors of HCW Biologics Inc., a Delaware corporation (the “Company”) approved and adopted an amendment to the Company’s Bylaws (as amended and restated to date, the “Bylaws”).

 

The amendment, which is effective from and after April 28, 2026, lowers the quorum requirement contained in Section 1.5 of the Bylaws to provide that holders of thirty-three and one-third percent (33 1/3%) of the voting power, which includes the voting power that is present in person or by proxy, regardless of whether the proxy has authority to vote on any matter, constitutes a quorum for the transaction of business (the “Amendment”). Prior to the Amendment, the Bylaws provided that the holders of a majority of the voting power of the shares of stock issued and outstanding and entitled to vote at the meeting, present in person or represented by proxy, constituted a quorum for the transaction of business.

 

The foregoing summary of the Amendment is qualified in its entirety by reference to the text of the Amendment, which is attached as Exhibit 3.2a to this Current Report on Form 8-K.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
3.2a   Amendment to the Bylaws of HCW Biologics, Inc.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      HCW BIOLOGICS INC.
       
Date: April 16, 2026 By: /s/ Hing C. Wong
      Hing C. Wong, Founder and Chief Executive Officer

 

 

FAQ

What change did HCW Biologics (HCWB) make to its quorum requirement?

HCW Biologics lowered the quorum needed to conduct stockholder business from a majority of voting power to 33 1/3% of voting power. This means fewer shares must be represented at a meeting, in person or by proxy, for corporate actions to proceed.

When does HCW Biologics’ new 33 1/3% quorum rule become effective?

The new 33 1/3% quorum rule becomes effective on April 28, 2026, after board approval on April 15, 2026. From that date, any stockholder meeting can transact business once at least one-third of the voting power is represented.

How did HCW Biologics’ prior Bylaws define a shareholder meeting quorum?

Previously, HCW Biologics required a majority of the voting power of shares issued, outstanding, and entitled to vote to be present or represented by proxy. Only when that majority was reached could a stockholder meeting conduct official corporate business.

Does HCW Biologics’ new quorum rule count proxies without voting authority?

Yes. The new quorum rule counts voting power present in person or by proxy, even if the proxy lacks authority to vote on particular matters. This broadened definition makes it easier to reach the 33 1/3% voting power threshold at meetings.

Where is the HCW Biologics Bylaw amendment on quorum filed in the 8-K?

The Bylaw amendment changing the quorum requirement is filed as Exhibit 3.2a to the current report. The 8-K notes that its brief description is qualified entirely by reference to the full text contained in that specific exhibit.

Filing Exhibits & Attachments

4 documents